Enveric Biosciences, a biotech company focused on neuroplastogen development, has entered a licensing agreement with MycoMedica Life Sciences, a clinical-stage biotechnology company, for its EVM201 program, including drug candidate EB-002.
Under the terms of the agreement, MycoMedica receives exclusive global rights to develop EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The deal includes potential milestone payments of up to USD 62 million plus tiered single-digit royalties on future sales, with MycoMedica assuming responsibility for all future development and commercialization.
Analyst QuickTake: In July 2024 , Enveric Biosciences secured a US patent for EB-002. This partnership enables Enveric to benefit from MycoMedica's commercialization of EB-002 through milestone payments and royalties, as it advances for neuropsychiatric treatments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.